CD19-Car T Cell Therapy（City Of Hope National Medical Center）

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameCD19-Car T Cell Therapy（City Of Hope National Medical Center）
Drug Alias NameAutologous Anti-CD19-CAR T cells therapy（City Of Hope National Medical Center）
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsCentral Nervous System LymphomaLymphomatoid GranulomatosisLymphoma, Large B-Cell, Diffuse +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCity Of Hope National Medical CenterNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteCity Of Hope National Medical Center
Inactive CompaniesN/A
Active IndicationsCentral Nervous System LymphomaLymphoma, Large B-Cell, DiffusePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsLymphomatoid GranulomatosisLymphoma, B-CellLymphoma, Non-Hodgkin +[6] 

Other Information

ATC CodeN/A
Related LinksN/A